GB9918965D0 - Chemical compounds xxi - Google Patents

Chemical compounds xxi

Info

Publication number
GB9918965D0
GB9918965D0 GBGB9918965.6A GB9918965A GB9918965D0 GB 9918965 D0 GB9918965 D0 GB 9918965D0 GB 9918965 A GB9918965 A GB 9918965A GB 9918965 D0 GB9918965 D0 GB 9918965D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds xxi
xxi
chemical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9918965.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Cerebrus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Ltd filed Critical Cerebrus Ltd
Priority to GBGB9918965.6A priority Critical patent/GB9918965D0/en
Publication of GB9918965D0 publication Critical patent/GB9918965D0/en
Priority to AU64554/00A priority patent/AU774337B2/en
Priority to DE60023146T priority patent/DE60023146T2/de
Priority to TR2002/00351T priority patent/TR200200351T2/xx
Priority to KR1020077014953A priority patent/KR20070086814A/ko
Priority to CNB008115168A priority patent/CN1167681C/zh
Priority to ES00951696T priority patent/ES2250167T3/es
Priority to US10/009,567 priority patent/US6962939B1/en
Priority to PCT/GB2000/003008 priority patent/WO2001012602A1/en
Priority to CA002377637A priority patent/CA2377637A1/en
Priority to MXPA01013252A priority patent/MXPA01013252A/es
Priority to EP00951696A priority patent/EP1202964B1/en
Priority to KR1020027001107A priority patent/KR20020015077A/ko
Priority to BR0013314-0A priority patent/BR0013314A/pt
Priority to JP2001517500A priority patent/JP2003507366A/ja
Priority to AT00951696T priority patent/ATE306470T1/de
Priority to PE2000000808A priority patent/PE20010575A1/es
Priority to ARP000104121A priority patent/AR030913A1/es
Priority to UY26290A priority patent/UY26290A1/es
Priority to ZA200110218A priority patent/ZA200110218B/xx
Priority to US11/117,459 priority patent/US7166613B2/en
Priority to US11/117,488 priority patent/US7173056B2/en
Priority to US11/117,460 priority patent/US7166632B2/en
Priority to US11/637,042 priority patent/US7323473B2/en
Priority to US11/637,082 priority patent/US7323487B2/en
Priority to US11/637,036 priority patent/US7323486B2/en
Priority to US11/984,734 priority patent/US20080125455A1/en
Priority to US11/984,735 priority patent/US20080114018A1/en
Priority to US11/987,774 priority patent/US20080090858A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GBGB9918965.6A 1999-08-11 1999-08-11 Chemical compounds xxi Ceased GB9918965D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB9918965.6A GB9918965D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxi
MXPA01013252A MXPA01013252A (es) 1999-08-11 2000-08-04 Derivados de indolina condensada y su uso como ligandos del receptor 5ht, en particular 5ht2c.
JP2001517500A JP2003507366A (ja) 1999-08-11 2000-08-04 縮合インドール誘導体および５ｈｔ、特に５ｈｔ２ｃのレセプターリガンドとしてのこれらの使用
AT00951696T ATE306470T1 (de) 1999-08-11 2000-08-04 Kondensierte indolinderivate und deren verwendung als 5ht, insbesondere 5ht2c, rezeptor liganden
TR2002/00351T TR200200351T2 (tr) 1999-08-11 2000-08-04 Yoğunlaştırılmış indolin türevleri, bunların 5HT, özellikle 5HT2C, reseptör ligandları olarak kullanımı
KR1020077014953A KR20070086814A (ko) 1999-08-11 2000-08-04 축합 인돌린 유도체들과 5ｈｔ, 특히 5ｈｔ2ｃ, 수용체리간드로서 이들의 사용
CNB008115168A CN1167681C (zh) 1999-08-11 2000-08-04 稠合二氢吲哚衍生物及其作为5ht特别是5ht2c受体配体的用途
ES00951696T ES2250167T3 (es) 1999-08-11 2000-08-04 Derivados condensados de indol y su uso como ligandos del receptor 5ht, en particular 5ht2c.
US10/009,567 US6962939B1 (en) 1999-08-11 2000-08-04 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
PCT/GB2000/003008 WO2001012602A1 (en) 1999-08-11 2000-08-04 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
CA002377637A CA2377637A1 (en) 1999-08-11 2000-08-04 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
DE60023146T DE60023146T2 (de) 1999-08-11 2000-08-04 Kondensierte indolinderivate und deren verwendung als 5ht-,insbesondere 5ht2c, rezeptorliganden
EP00951696A EP1202964B1 (en) 1999-08-11 2000-08-04 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
KR1020027001107A KR20020015077A (ko) 1999-08-11 2000-08-04 축합 인돌린 유도체들과 5ｈｔ, 특히 5ｈｔ2ｃ, 수용체리간드로서 이들의 사용
BR0013314-0A BR0013314A (pt) 1999-08-11 2000-08-04 Composto quìmico de derivados de indolina, seu uso e método de preparação, método de tratamento, composição farmacêutica e método de fabricação de uma composição que o contém
AU64554/00A AU774337B2 (en) 1999-08-11 2000-08-04 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
PE2000000808A PE20010575A1 (es) 1999-08-11 2000-08-09 Derivados de indol y su uso como ligandos del receptor 5ht2
ARP000104121A AR030913A1 (es) 1999-08-11 2000-08-10 Un compuesto derivado de indolina, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y un procedimiento para preparar dicha composicion
UY26290A UY26290A1 (es) 1999-08-11 2000-08-11 Compuestos químicos xxi
ZA200110218A ZA200110218B (en) 1999-08-11 2001-12-12 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands.
US11/117,460 US7166632B2 (en) 1999-08-11 2005-04-29 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US11/117,459 US7166613B2 (en) 1999-08-11 2005-04-29 Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands
US11/117,488 US7173056B2 (en) 1999-08-11 2005-04-29 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US11/637,042 US7323473B2 (en) 1999-08-11 2006-12-12 Condensed indoline derivatives and their use as 5-HT, in particular 5-HT2C, receptor ligands
US11/637,082 US7323487B2 (en) 1999-08-11 2006-12-12 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US11/637,036 US7323486B2 (en) 1999-08-11 2006-12-12 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US11/984,734 US20080125455A1 (en) 1999-08-11 2007-11-21 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands
US11/984,735 US20080114018A1 (en) 1999-08-11 2007-11-21 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US11/987,774 US20080090858A1 (en) 1999-08-11 2007-12-04 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918965.6A GB9918965D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxi

Publications (1)

Publication Number Publication Date
GB9918965D0 true GB9918965D0 (en) 1999-10-13

Family

ID=10858983

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9918965.6A Ceased GB9918965D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxi

Country Status (19)

Country Link
US (10) US6962939B1 (enExample)
EP (1) EP1202964B1 (enExample)
JP (1) JP2003507366A (enExample)
KR (2) KR20070086814A (enExample)
CN (1) CN1167681C (enExample)
AR (1) AR030913A1 (enExample)
AT (1) ATE306470T1 (enExample)
AU (1) AU774337B2 (enExample)
BR (1) BR0013314A (enExample)
CA (1) CA2377637A1 (enExample)
DE (1) DE60023146T2 (enExample)
ES (1) ES2250167T3 (enExample)
GB (1) GB9918965D0 (enExample)
MX (1) MXPA01013252A (enExample)
PE (1) PE20010575A1 (enExample)
TR (1) TR200200351T2 (enExample)
UY (1) UY26290A1 (enExample)
WO (1) WO2001012602A1 (enExample)
ZA (1) ZA200110218B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
BR0211140A (pt) * 2001-07-13 2005-10-25 Upjohn Co Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
AR046890A1 (es) * 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006062839A1 (en) * 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
DE102006033114A1 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
PL3250549T3 (pl) 2015-01-29 2021-12-13 The Board Of Trustees Of The University Of Illinois Cyklopropylometanoaminy jako selektywni agoniści receptora 5-HT(2C)
WO2018151240A1 (ja) * 2017-02-17 2018-08-23 第一三共株式会社 ３，６，７，８－テトラヒドロシクロペンタ［ｅ］インドール化合物
WO2018151239A1 (ja) * 2017-02-17 2018-08-23 第一三共株式会社 ３，６－ジヒドロ－２Ｈ－フロ［２，３－ｅ］インドール化合物
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3329571A (en) 1961-10-24 1967-07-04 American Home Prod Methods for treating depression
US3142678A (en) 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (enExample) 1993-10-22 1996-02-11 Hoffmann La Roche
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
TW403738B (en) 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
FR2742047B1 (fr) * 1995-12-06 1998-01-16 Oreal Compositions de teinture des fibres keratiniques contenant des derives n-substitues de la 4-hydroxy indoline, nouveaux derives, leur procede de synthese, leur utilisation pour la teinture, et procede de teinture
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi

Also Published As

Publication number Publication date
US20050187282A1 (en) 2005-08-25
KR20070086814A (ko) 2007-08-27
AR030913A1 (es) 2003-09-03
UY26290A1 (es) 2001-03-16
MXPA01013252A (es) 2002-06-04
CN1379761A (zh) 2002-11-13
PE20010575A1 (es) 2001-05-21
US6962939B1 (en) 2005-11-08
EP1202964A1 (en) 2002-05-08
ES2250167T3 (es) 2006-04-16
US7173056B2 (en) 2007-02-06
JP2003507366A (ja) 2003-02-25
KR20020015077A (ko) 2002-02-27
US20050192334A1 (en) 2005-09-01
TR200200351T2 (tr) 2002-06-21
WO2001012602A1 (en) 2001-02-22
ZA200110218B (en) 2002-12-12
US7166632B2 (en) 2007-01-23
US7323486B2 (en) 2008-01-29
US20070099981A1 (en) 2007-05-03
DE60023146T2 (de) 2006-07-06
BR0013314A (pt) 2002-04-02
US20050197380A1 (en) 2005-09-08
US20070105889A1 (en) 2007-05-10
CN1167681C (zh) 2004-09-22
AU774337B2 (en) 2004-06-24
CA2377637A1 (en) 2001-02-22
AU6455400A (en) 2001-03-13
US20080125455A1 (en) 2008-05-29
US7166613B2 (en) 2007-01-23
DE60023146D1 (de) 2006-02-23
EP1202964B1 (en) 2005-10-12
US20080090858A1 (en) 2008-04-17
US7323487B2 (en) 2008-01-29
ATE306470T1 (de) 2005-10-15
WO2001012602A8 (en) 2001-04-05
US20070099980A1 (en) 2007-05-03
US20080114018A1 (en) 2008-05-15
US7323473B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
GB9907658D0 (en) Chemical compounds
GB9902461D0 (en) Chemical compounds
GB9909409D0 (en) Chemical compounds
GB9903861D0 (en) Chemical compounds
GB9910104D0 (en) Chemical compounds
GB9910110D0 (en) Chemical compounds
GB9900078D0 (en) Chemical compounds
GB9914024D0 (en) Chemical compounds
GB9910394D0 (en) Chemical compounds
GB9914015D0 (en) Chemical compounds
GB9914022D0 (en) Chemical compounds
GB9908355D0 (en) Chemical compounds
GB9910419D0 (en) Chemical compounds
GB9912640D0 (en) Chemical compounds
GB0001663D0 (en) Chemical compounds
GB9909062D0 (en) Chemical compounds
GB9906564D0 (en) Chemical compounds
GB9910421D0 (en) Chemical compounds
GB9909442D0 (en) Chemical compounds
GB9906565D0 (en) Chemical compounds
GB9903859D0 (en) Chemical compounds
GB9903532D0 (en) Chemical compounds
GB9910674D0 (en) Chemical compounds
GB9904506D0 (en) Chemical compounds
GB9901795D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)